Pixelgen's $15.5M Bet on Mapping Proteins Could Change Disease Research

Jan de Vries · 2026-08-20

What if we could see how proteins are arranged on a single cell the way we see stars in a constellation? That's the big idea behind Pixelgen Technologies, a Stockholm-based life sciences company that just closed a hefty funding round to make that vision a reality. The company has raised $15.5 million in an oversubscribed Series B round, and the implications for cancer research, immunology, and even basic biology are worth paying attention to. ### Who's Backing This and Why It Matters The round was led by Flat Capital, a new investor, with existing backers Industrifonden and Navigare Ventures doubling down. Along with the cash, Pixelgen is bringing two sharp minds onto its board: Rickard El Tarzi, CEO of Flat Capital, and Ramon Felciano, Ph.D., a seasoned life sciences executive. That's a clear signal that the company isn't just looking for money; it's seeking strategic muscle to scale up. "This financing gives us the resources to expand globally as demand grows for our Proxiome Kit and our data analysis and visualisation software," said Pixelgen CEO and co-founder Simon Fredriksson, Ph.D. "Their support will help accelerate our commercial reach, grow our team and product portfolio, and bring molecular cell architecture to more researchers and new applications." ### The Tech That's Turning Heads Here's the part that gets scientists excited. Traditional proteomics tells you how much of a protein is present in a sample. It's like counting how many cars are in a parking lot. Pixelgen's Proxiome Kit, however, shows you where those cars are parked, how they're clustered, and how they're oriented relative to each other. That's the difference between knowing a protein exists and understanding how it functions in its natural environment. The kit uses something called the Proximity Network Assay to map molecular architecture at nanoscale resolution. That's incredibly small—we're talking about features a thousand times thinner than a human hair. This level of detail could reveal disease mechanisms that abundance measurements simply miss. For researchers studying cell therapy, oncology, or autoimmune diseases, this is a potential goldmine of new insights. "Pixelgen's technology gives researchers the ability to study disease mechanisms and identify novel biomarkers in an entirely new way," said El Tarzi. "We believe this could open new avenues for research in cancer, immunology, and autoimmune disease, while broadening our understanding of basic biology." ### A Quick Look at the Journey Pixelgen was founded in 2020 by Fredriksson along with Alvaro Martinez Barrio, Ph.D., Fredrik Dahl, Ph.D., and Filip Karlsson. The company came out of stealth in December 2022 after a $6 million seed round led by Navigare Ventures. Since then, it's been on a steady climb: - **October 2023:** Closed a Series A of approximately $7.3 million, led by Industrifonden and Navigare Ventures. - **June 2025:** Awarded $14.7 million in grant and equity financing from the European Innovation Council (EIC) Accelerator. - **Now:** $15.5 million Series B to fuel global expansion. That's a solid track record of investor confidence, and it's not hard to see why. The company's leadership team has a history of commercializing life sciences products on a global scale. ### What's Next for Pixelgen The fresh capital is earmarked for accelerating the global rollout of the Proxiome Kit and expanding its footprint in key markets. The goal is to get this technology into more labs, working on more applications, and ultimately helping researchers answer questions they couldn't even ask before. Whether you're a scientist, an investor, or just someone curious about the future of medicine, this is a story worth following. The ability to see how proteins organize on a cell surface could be the key to unlocking new treatments for some of the toughest diseases we face. And with this new funding, Pixelgen is positioning itself to be at the forefront of that discovery.